These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24139347)

  • 21. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study.
    Haider KS; Haider A; Doros G; Traish A
    J Urol; 2018 Jan; 199(1):257-265. PubMed ID: 28728990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism.
    Karazindiyanoğlu S; Cayan S
    Aging Male; 2008 Sep; 11(3):146-9. PubMed ID: 18821291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Patient with TDS and lower urinary tract symptoms (LUTS)].
    Romero-Otero J; García B; Jiménez Alcalde E; García Cruz E; Leibar Tamayo A; Rodríguez Antolín A
    Arch Esp Urol; 2013 Sep; 66(7):657-62. PubMed ID: 24047623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study.
    Yassin DJ; El Douaihy Y; Yassin AA; Kashanian J; Shabsigh R; Hammerer PG
    World J Urol; 2014 Aug; 32(4):1049-54. PubMed ID: 24135918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
    Saad F; Yassin A; Doros G; Haider A
    Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms.
    Lee RK; Chung D; Chughtai B; Te AE; Kaplan SA
    BJU Int; 2012 Aug; 110(4):540-5. PubMed ID: 22243806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
    Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
    BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OnabotulinumtoxinA injection therapy in men with LUTS due to primary bladder-neck dysfunction: objective and patient-reported outcomes.
    Sacco E; Tienforti D; Bientinesi R; D'Addessi A; Racioppi M; Pinto F; Totaro A; Vittori M; D'Agostino D; Bassi P
    Neurourol Urodyn; 2014 Jan; 33(1):142-6. PubMed ID: 23868794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial comment.
    Morales A
    Urology; 2014 Jan; 83(1):173-4; discussion 174. PubMed ID: 24139349
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.